Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.

@article{Schulz2008OlanzapineFT,
  title={Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.},
  author={S. Charles Schulz and Mary C. Zanarini and Anthony W. Bateman and Martin Bohus and Holland C. Detke and Quynh N Trzaskoma and Yoko Tanaka and Daniel Lin and Walter G Deberdt and Sara A Corya},
  journal={The British journal of psychiatry : the journal of mental science},
  year={2008},
  volume={193 6},
  pages={
          485-92
        }
}
BACKGROUND Despite the prevalence and clinical significance of borderline personality disorder, its treatment remains understudied. AIMS To evaluate treatment with variably dosed olanzapine in individuals with borderline personality disorder. METHOD In this 12-week randomised, double-blind trial, individuals received olanzapine (2.5-20 mg/day; n=155) or placebo (n=159) (trial registry: NCT00091650). The primary efficacy measure was baseline to end-point change on the Zanarini Rating Scale… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
22 Extracted Citations
40 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 22 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 40 references

Similar Papers

Loading similar papers…